Cosmo Pharmaceuticals N.V. reiterated earnings guidance for the Year 2023 . For the year, company expects total revenue between EUR 110 million and EUR 120 million, operating profit between EUR 25 million and EUR 35 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
71.95 CHF | -1.03% | -1.78% | +40.67% |
Apr. 26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.67% | 1.28B | |
+38.69% | 728B | |
+33.83% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+16.04% | 244B | |
+7.73% | 207B | |
-5.60% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023